1/24
05:09 am
jagx
Jaguar Animal Health (NASDAQ:JAGX) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Jaguar Animal Health (NASDAQ:JAGX) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
1/24
12:30 am
jagx
Jaguar Animal Health (NASDAQ:JAGX) was downgraded by analysts at
Wall St
Low
Report
Jaguar Animal Health (NASDAQ:JAGX) was downgraded by analysts at
Wall St
1/22
09:15 am
jagx
Jaguar Health Highlights Sharp Strategic Focus on Rare Intestinal Failure Diseases Fueled by Non-Dilutive Funds from Closing of License Deal for Mytesi [Yahoo! Finance]
Medium
Report
Jaguar Health Highlights Sharp Strategic Focus on Rare Intestinal Failure Diseases Fueled by Non-Dilutive Funds from Closing of License Deal for Mytesi [Yahoo! Finance]
1/6
09:12 am
jagx
Article About Groundbreaking Results from Study of Jaguar Health's Crofelemer for Treatment of Intestinal Failure Featured in United Arab Emirates Healthcare Publication [Yahoo! Finance]
Medium
Report
Article About Groundbreaking Results from Study of Jaguar Health's Crofelemer for Treatment of Intestinal Failure Featured in United Arab Emirates Healthcare Publication [Yahoo! Finance]
12/10
09:13 am
jagx
FDA Approves Renewal of Canalevia-CA1, Jaguar Health's Drug for Chemotherapy-Induced Diarrhea (CID) in Dogs [Yahoo! Finance]
Medium
Report
FDA Approves Renewal of Canalevia-CA1, Jaguar Health's Drug for Chemotherapy-Induced Diarrhea (CID) in Dogs [Yahoo! Finance]
11/18
06:19 am
jagx
Jaguar Health Reports Third Quarter 2025 Financials: Net Q3 2025 Revenue Up Approximately 4% Versus Net Q2 2025 Revenue [Yahoo! Finance]
Medium
Report
Jaguar Health Reports Third Quarter 2025 Financials: Net Q3 2025 Revenue Up Approximately 4% Versus Net Q2 2025 Revenue [Yahoo! Finance]
11/17
10:20 am
jagx
Jaguar Health, Inc. (JAGX) Q3 2025 Earnings Call Prepared Remarks Transcript [Seeking Alpha]
Low
Report
Jaguar Health, Inc. (JAGX) Q3 2025 Earnings Call Prepared Remarks Transcript [Seeking Alpha]
11/17
10:19 am
jagx
Jaguar Health outlines dual NDA filing targets for late 2026 as clinical catalysts converge [Seeking Alpha]
Low
Report
Jaguar Health outlines dual NDA filing targets for late 2026 as clinical catalysts converge [Seeking Alpha]
11/17
08:33 am
jagx
Jaguar Health GAAP EPS of -$6.28, revenue of $3.08M [Seeking Alpha]
Low
Report
Jaguar Health GAAP EPS of -$6.28, revenue of $3.08M [Seeking Alpha]